Background: Pediatric opsoclonus-myoclonus syndrome (OMS) presents a paradox of etiopathogenesis: A neuroblastic tumor (NB) is found in only one half of the cases, the others are ascribed to infections or designated as idiopathic.
INTRODUCTION
Opsoclonus-myoclonus syndrome (OMS), alias opsoclonusmyoclonus-ataxia syndrome, is an inflammatory neurologic syndrome with a strong connection to cancer. [1] [2] [3] Tumors are usually neuroblastic (NB), residing in the body cavity, inclusive of neuroblastoma, Abbreviations: CCL, C-C motif chemokine ligand; CD, cluster of differentiation; CSF, cerebrospinal fluid; CXCL, C-X-C motif chemokine ligand; IL, interleukin; MIBG, metaiodobenzylguanidine; NB, neuroblastoma; NMDAR, N-methyl-D-aspartate receptor; NT, neuroblastic tumor; OMES, Opsoclonus-Myoclonus Evaluation Scale; OMS, opsoclonus-myoclonus syndrome; TS, total score The diagnostic paradox is that a paraneoplastic etiology can only be proven presently in about 50% of the cases. 4 One proposed explanation is missed tumors. Compared to their often-aggressive counterparts without OMS, 8, 9 NB can be more difficult to detect in OMS due to a lower frequency of metaiodobenzylguanidine (MIBG) uptake and urinary catecholamine secretion. 10 These differences may elude or delay diagnosis. NB, arising from the developing sympathetic nervous system, 8 may also regress spontaneously. 11 Although OMS "etiology" has been defined largely through diagnostic tumor imaging studies, there is no consensus on the optimal type, number, or frequency of scans. 12 An alternative explanation is that tumors are not the only provocation for OMS. Imaging-negative cases have been designated as "parainfectious," 13, 14 "post-infectious," [15] [16] [17] or "idiopathic," 18, 19 usually on the basis of whether "prodromal" (preneurological) symptoms were interpreted as suggestive of infection. 20 Despite a litany of infections reported in case studies, 14, 16, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] some with intrathecal inflammation, no consistent pathogen has been identified, 3 the infection is usually nondeclaratory (nondemonstrable), 10 and patients may have no "infectious" prodrome. 20 The biological validity of OMS etiological designations has been enigmatic and difficult to address. Are there two portals of entry to a uniform pathogenesis or two separate but equal pathways with shared downstream events? 12 Besides being intellectually dissatisfying and confusing, this dichotomization has practical consequences for the extent of diagnostic testing, the treatment of OMS, and which type of specialist handles the case. Lack of data in this rare disorder has resulted in an inability to systematically classify patients, frame viable hypotheses, and rethink strategies for translational research on the issue.
The present study accepts the compelling reason and unique opportunity to study multiple factors that may be involved. To approach the problem, we performed extensive secondary analysis of just the US cases of a well-defined population of pediatric-onset OMS. 4 Primary analysis of the data, which did not address this issue, is not reiterated here. Demographic, neurologic, oncologic, epidemiologic, neuroimmunologic, and neuropharmacologic data were examined in an effort to differentiate the purported OMS etiologies in the largest US patient population yet applied for this purpose. The main questions were: (1) is OMS phenotypically different depending on the perceived etiology?; (2) what is the evidence for or against a true etiologic dichotomy?;
and (3) what approaches would be required to reach a definitive answer? The present report extends knowledge about OMS in the aggregate, including our experience with its neuroinflammation [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] which involves immune cells and mediators that foster the neogenesis of lymphoid follicles. 48 
METHODS

Participants
The objective of the study was to compare patients with a demonstrated NB ("Tumor") with those in whom no tumor was found ("No Tumor"). Cross-sectional clinical and demographic features, OMS onset age distribution, prodromal symptoms, time to OMS diagnosis, OMS duration, geographical distribution, ranked order of neurological signs, neuroimmunologic markers in CSF and blood, and early neuropharmacologic responses were evaluated. This was a monocenter, observational study analyzed retrospectively. All patients had been evaluated by the first two authors at the National Pediatric Myoclonus Center specializing in pediatric-onset OMS. The OMS population, a representative cohort, comprised 356 children with clinically confirmed OMS. Data were collected previously by written parental consent for the IRB-approved study SIU SOM, Springfield, IL). Additionally, Western IRB (Puyallup, WA) granted permission for retrospective analysis. Secondary analysis of the data was used to address the question of OMS etiology with literature as supporting documents.
The opsoclonus-myoclonus evaluation scale (OMES) used for assessing OMS severity is reprinted in Supplementary Table S1 . Extensive methodological details were provided with the primary analysis. 4 
Tumor screening
NB type, location, and stage are shown in Supplementary Table S2 .
We did not have access to formal risk classification, 49 but 93% of the patients had stage 1 or 2 tumors; 7%, stage 3 or 4.
At the time of our evaluation, most patients had been screened for NB, but the types and number of tests were not uniform. Among them were urinary catecholamines; CXR and abdominal ultrasound; MRI of neck, chest, abdomen, and pelvis; CT with oral and intravenous contrast; and MIBG scan. If a tumor had not been found, screening was broadened to include tests not performed previously, making sure both anatomic imaging methods (CT, MRI) and functional imaging scintigraphy ([123I]MIBG) had been employed. [50] [51] [52] It was also our standard practice (not result of study) to recommend MRI reimaging at 6-month intervals for 2 years after OMS onset in imaging-negative cases, and at the time of unexplained OMS relapse or failure to remit on immunotherapy. 12 Patients already shown to have a NB were monitored by their oncologist for tumor recurrence per standard of care.
Possible under-reporting of late tumor detection by parents over the years was anticipated. The majority of families stayed in touch with us, but it was not possible to contact every family to determine if a tumor was subsequently detected in tumor-negative cases.
Commercial screening for "paraneoplastic" autoantibodies and antibodies associated with autoimmune encephalitis was so seldom positive, 4 results were not dichotomized. ther methodologic details and our data from non-inflammatory pediatric neurological controls have been reported previously. 36, 37 Dichotomized flow cytometric data on the CXCR3+CD4+ T-cell receptor 43 are shown in Supplementary Table S3 .
Enzyme-linked immunosorbent assays
Enzyme-linked immunosorbent assays (ELISA) were used to measure the cytokines B-cell activating factor (BAFF) and a proliferationinducing ligand (APRIL), C-C motif chemokine ligands 19 (CCL19) and 21 (CCL21), as well as the C-X-C motif chemokine ligands 10 (CXCL10), 12 (CXCL12), and 13 (CXCL13). Assay kits were purchased from R&D Systems (Minneapolis, MN), except for the APRIL kit, which was purchased from eBioscience (Vienna, Austria). Corresponding control data from the principal investigator's laboratory have been published. 42, 43, 45, 47 Our dichotomized data on ELISA-measured Th2 chemokines (CCL17, CCL22), 44 soluble cell adhesion molecules (sICAM-1, sVCAM-1), 39 and neuronal/glial markers (NFL, GFAP) 40 are presented in Supplementary Table S3 . A P-value < 0.05 was considered statistically significant throughout.
Multiplexed fluorescent bead-based immunoassays
Bonferroni corrections were made for multiple corrections ( at 0.05/n of comparisons).
RESULTS
Demographic characteristics of OMS with and without tumor
The cardinal demographic characteristics are shown in Table 1 . Patient age was wide-ranging but well balanced between groups, with no statistically significant differences in means/medians. The racial/ethnic demography for children with a demonstrated NB did not differ statistically from those without. Patient gender frequency also did not discriminate the two groups, though there appeared to be a slightly greater female predominance in the tumor group.
Neurological severity by perceived OMS etiology
Mean total score (TS) of the OMES fell within the moderate severity category of 13-24 and was not significantly different between groups (Table 1) . ANOVA revealed a comparable statistically significant effect of OMS duration category on TS in the Tumor (P < 0.0001) and No
Tumor groups (P < 0.0001), but no significant effect of perceived OMS etiology. The proportion of OMS duration categories in the two groups was very similar.
Onset-age distribution of OMS with and without tumor
There were no statistically significant differences in the mean OMS age-of-onset frequency (Fig. 1) . Both groups showed the greatest prevalence between the ages of 1-2 years. The rise in frequency was steeper on the left side of the peak age; and decline in frequency on the right was more gradual, with a low frequency after the age of 4.5-7.5
years. In a month-by-month breakdown of children with OMS over the first 2 years (Fig. 1, inset) , both etiologies were represented. OMS onset age was slightly higher in the No Tumor group, owing to late-onset cases. To determine the timing of the difference, age cutoffs were analyzed. Using a cut-off of ≤ 2 years, the OMS onset age was not statistically different in the two groups: 5.5 ± 4.6 months (n = 131, Tumor); 5.2 ± 4.4 (n = 126, No Tumor). It was no different with the age cut-off of <4 years either: 1.6 ± 0.7 years (n = 169); 1.7 ± 0.7 (n = 167), respectively. The difference became significant at the age cut-off of ≤ 5 years due to late onset cases primarily in the No Tumor group.
Prodromal symptoms by perceived OMS etiology
Prodromal symptoms were similar in type and frequency between the two groups (Fig. 3A) . Fever and ear infection did not discriminate the groups. The most prevalent symptoms, crying and irritability, were general in nature. Neither vomiting/diarrhea (possibly suggestive of In the Tumor group, specific infections recalled by parents in the weeks immediately preceding OMS onset included: "rotavirus" (n = 2), "Coxsackie" (n = 1), "chickenpox" (n = 2), "croup" (n = 1), "flu" (n = 1),
"thrush" (n = 1), "laryngitis" (n = 1). In the No Tumor group, there was "pink eye" (n = 1), "strep throat" (n = 1), "wheezing" (n = 1), and "upper respiratory infection" (n = 1).
Time to OMS diagnosis
The average time to diagnosis of OMS, which varied widely, did not differ statistically in the two groups. When clinically convenient cutpoints were assigned, about one-half of the patients were diagnosed within the first month and three quarters by 3 months, but one-fifth were diagnosed only in the second half of the first-year post-onset.
OMS etiology had no statistically significant effect in this frequency analysis.
OMS duration
There was no statistically significant effect of apparent OMS etiology on mean OMS duration.
Geographic distribution of OMS cases identified as tumor versus no tumor
The data were analyzed for geographical or latitudinal patterns. By visual inspection, there was no apparent difference in the geographical distribution of patients with tumor versus no tumor (Fig. 2) . There was an admixture in populated areas, and, in other areas, the distribution seemed random and not mutually exclusive. There was no obvious difference in designated tumor cases in rural versus metropolitan areas.
Also, there were no latitudinal differences in geographic distribution, which might be found for some vectors, between the two groups. 
Ranked order of neurologic signs
The order of appearance of 10 neurological signs was statistically significance for Tumor (P < 0.0001) and No Tumor groups (P < 0.0001). In both, signs of gait ataxia (staggering and falling) were earliest. Although the same kinds of neurological signs were present in both groups, there was no statistically significant inter-group difference in frequencies (Fig. 3B ).
Relapse history
Based on OMS relapse history at the time of evaluation, there were more nonrelapsers than relapsers in either group. However, the proportion of patients with and without relapse was not significantly different in the Tumor and No Tumor groups. 
Neuroimmunologic markers
The results of assays for CSF lymphocyte subsets (immunophenotype), chemokines and other cytokines, and brain-related proteins in OMS were compared in the two groups (Table 2) . No statistically significant group differences were found after Bonferroni corrections for multi- 
Early neuropharmacologic responses by history
The proportion of untreated, currently treated (on arrival), and previously (not currently) treated subgroups was comparable in the Tumor and No Tumor groups (Fig. 4A) . The majority of patients were on immunotherapy at the evaluation; some were polymedicated with conventional agents. There were 141 treated patients in the Tumor group (87%) and 118 in the No Tumor group (73%). There was a statistically significant difference between the two groups only in the number of agents the patients had received (P = 0.002, Chi-square). In the Tumor group, 18.5% had received a single agent; 81.5% received two or more agents. In the No Tumor group, 36.5% had received monotherapy, and 63.5% received two or more agents.
As anticipated, TS was significantly higher in untreated than treated OMS (Fig. 4B) , however, mean total scores of treated patients were in the moderate severity range whether patients arrived on immunotherapy or had only received it previously, despite the fact that OMS duration was longer in the previously treated group (Fig. 4C) . No significant effect of OMS etiology was found.
The time to treatment appeared slightly longer for ACTH than for
IVIg and prednisone, but was comparable in Tumor and No Tumor groups (Fig. 4D) . The frequency of "dramatic response" to therapy with prednisone, ACTH, or IVIg was analyzed (Fig. 4E ). More patients were reported by parents to respond to ACTH (80%) than to prednisone or IVIg (each 50%), but there was no apparent effect of OMS etiology on the response.
TS was significantly lower (−22%) in patients treated with two or more agents than monotherapy (P = 0.002) when treated OMS were combined, but the statistical significance was less in group analysis (Fig. 4F ).
DISCUSSION
The main finding of this population-based study was that neurologic, oncologic, epidemiologic, neuroimmunologic, and neuropharmacologic data in the largest reported cohort of children with OMS failed to differentiate OMS in the group designated as "paraneoplastic" from that designated as "para/post-infectious" or "idiopathic." Barring demonstration of the tumor, resection scar, or visible tumor or surgical complications, such as Horner syndrome, the clinical phenotype of the groups was indistinguishable. Perceived OMS etiology had no bearing on the OMS signs, as speculated previously in some small case series. 36, 53 Because the literature offers incomplete and sometimes conflicting evidence on this point, the present study, which encompasses the contradictions, makes a contribution.
Interpretation should be mindful that the conclusions of the current study pertain to children up to the age of 9.8 years, which is also the main prevalence of NB (90% diagnosed by the age of 5 years; rare in people > 10 years). 54 OMS occurrence in adolescence, which is uncommon, cannot be addressed by these data. Infections with a self-limited course have been reported in tweens and teens, 13 and data on OMS in that late-onset age group are too scant to extrapolate. 
TA B L E 2 Cross-sectional comparison of neuroinflammatory markers based on tumor detection in OMS
Primarily T cell
[sIL-2Ra] pg/ml 426 ± 237 421 ± 240 0.89
[IL12p40] pg/ml 204 ± 161 232 ± 229 0.43
Data are means ± SD. N values are italicized and in parentheses below the means. APRIL, a proliferation inducing ligand; BAFF, B-cell activating factor; CCL19, C-X-C motif chemokine ligand 19; GFAP, glial fibrillary acidic protein; CXCL13, C-X-C motif chemokine ligand 13; CXCR3, C-X-C motif chemokine receptor 3; IL-1Ra, interleukin-1 receptor antagonist; IL12p40, interleukin-12 p40 subunit. CXCL12 was measured in plasma. After Bonferroni corrections, there were no statistically significant differences between groups per t-tests.
The results of this study challenge the existing dogma that OMS The hypothesis that OMS does not have a uniform paraneoplastic causation (Hypothesis 2) is also based on supporting data. Virusinduced diseases of the CNS are widespread, 58 not rare like NB. Of the potential pathogens described in OMS, some are neurotropic 59 and/or associated with CSF pleocytosis. 13, 14, 22, 25, 29, 31 If the CSF culture is negative and CSF leukocyte count is normal, the etiology is more likely interpreted as parainfectious than infectious. A post-infectious designation is established for certain other neuroimmunologic disorders, such as acute cerebellar ataxia, 60 so there is precedent. Proposed mechanisms of virus-induced autoimmune response include molecular mimicry, direct bystander activation, epitope spreading, virus-induced "decoy," and release of "cryptic epitopes." 61, 62 Lack of tumor demonstration in 50% of cases may be a lot to attribute to failures of screening techniques and spontaneous regression. In short-lived OMS associated with transient illnesses, 63 remission may occur spontaneously. 60 Illnesses are a common trigger for OMS relapse 12 ;
de novo neuroinflammatory disease also has been postulated. 11 The possible role of immunizations as triggers has not been discussed due to insufficient data.
Which of these hypotheses, or others, on OMS etiology is correct cannot be determined from the data available presently and awaits discovery. Specific immunopathophysiologic mechanisms are unknown.
This conundrum is not limited to NB and OMS. An apparent duality of causation also upends a uniform model of autoimmune encephalitis, in which ovarian teratoma-rare in OMS 64 -is found in a percentage of females that increases with age: 9% in those < 14 years old, 30% in those < 18 years old, and 56% of those > 18 years old. 65, 66 In To help interpret the immunological data in the present study, it should be realized that OMS has been shown to be a neuroinflammatory disorder; the designation "autoimmune," which has different implications and is not used interchangeably, is suspected, not proven. Advances in research implicating cellular and humoral involvement in OMS over the past two decades have been published in immunology and neuroimmunology journals and may not be known to treating physicians. First, pathologic CSF B-cell expansion in OMS was the evidence-based reason to treat with rituximab. 37, 41 The reduced CD4/CD8 ratio suggests T-cell dysregulation. CSF concentrations of chemokine CXCL13, a B-cell attractant; chemokine CXCL10, an inflammatory chemokine; BAFF, a B-cell activating factor;
and cytokine IL-6, a stimulator of antibody production are all elevated in OMS. [36] [37] [38] [39] 41, 43, 46, 47 The CSF concentration of the axonal/neuronal marker neurofilament light chain, the first biochemical demonstration of axonal/neuronal injury in OMS, was also increased. 40 Second, high dose steroid and corticotropin reduce the concentrations of inflammatory mediators (not CSF immune cell frequencies) 36 to varying degrees whether NB was found or not. 39, 40, [42] [43] [44] [45] [46] [47] Lack of significant differences in these parameters based on apparent OMS etiology is striking.
A great strength of the study was the unprecedented large sample size for pediatric OMS. The multiparameter approach was novel.
Patients were systematically evaluated by the same examiners with OMS expertise, and state-of-the-art neuroimmunologic biomarker testing was performed in the same reference laboratory. The multidisciplinary sources of data were also an important asset. Two testable hypotheses were framed along with a synopsis of the supporting literature.
As a limitation, the conclusions are based on the study parameters, and there may be other potentially useful discriminators outside the scope of the study or currently unavailable. Tertiary expert centers for OMS may see more persistent cases than extremely transient ones and may underestimate parainfectious cases. Complete data on types of NB imaging studies or pathogen studies were not available, and this
was not a long-term outcome study. Some data are descriptive and associations are reported.
In summary, this large study reveals striking similarities (indistinguishable features) between the "paraneoplastic" and "parainfec- 
